Project Grant R43DA050400

This $1.59 million Project Grant, awarded September 1, 2025, by the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to discover and develop GPR52 ligand probes as novel therapeutic candidates for cocaine use disorder (CUD). The University of Texas Medical Branch at Galveston will conduct basic and translational research to identify selective small molecule G protein-biased agonists targeting GPR52, a novel orphan G...

Federal Project Grant Award Summary Psychogenics Inc. received a $398,947 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) awarded June 15, 2026, with an ultimate completion date of May 31, 2027. The grant funds preclinical research and development services to evaluate two novel molecular compounds as potential pharmacotherapies for cocaine use disorder (CUD). Psychogenics will conduct behavioral studies using its...

Federal Project Grant Award Summary Wake Forest University Health Sciences received a $1,406,298 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective September 1, 2025, through May 31, 2030. The award funds research examining nociceptin/orphanin FQ peptide (NOP) receptors as therapeutic targets for cocaine use disorder (CUD) treatment, addressing a significant public health gap where no FDA-approved medications...

Federal Project Grant Award Summary Astrocyte Pharmaceuticals Inc. received a $399,680 Project Grant from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct preclinical research on AST-004, a novel therapeutic candidate for psychostimulant use disorder. The award, dated July 15, 2026, supports research through June 30, 2027, to evaluate the efficacy of oral AST-004 in reducing cocaine and methamphetamine self-administration and...

The University of Pennsylvania received a $527,837 Project Grant award from the National Institute on Drug Abuse, part of the Department of Health and Human Services, to study altered midbrain GABAergic circuitry and its role in driving greater cocaine self-administration. Specifically, the researchers will characterize the functional state of midbrain GABAergic circuitry and the disposition of the KCC2 potassium-chloride cotransporter during cocaine self-administration, extinction, and...

Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Wake Forest University Health Sciences a $952,155 Project Grant effective August 15, 2025, through April 30, 2030, under the Drug Use and Addiction Research Programs (CFDA 93.279). This research project investigates the impact of nicotine and alcohol co-use on cocaine abuse potential using cynomolgus monkey models to address cocaine use disorder (CUD), a major public health challenge with no FDA-approved...

Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of California, Santa Barbara $645,966 under the Drug Use and Addiction Research Programs (CFDA 93.279) on June 15, 2026, for a Project Grant extending through March 31, 2031. This award funds preclinical research to advance pharmacological interventions targeting psychostimulant use disorder (PUD), addressing the absence of FDA-approved medications for cocaine and methamphetamine addiction. The...

Federal Grant Award Summary The University of Kentucky Research Foundation received a $663,978 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) effective May 1, 2026, with completion anticipated by February 28, 2031. The award funds a translational research project evaluating Cobenfy, a newly FDA-approved muscarinic acetylcholine receptor agonist medication, as a potential therapeutic intervention for cocaine...

This five-year, $573,638 project grant from the National Institute on Drug Abuse, part of the Department of Health and Human Services, supports research into the neural mechanisms of individual differences in cocaine avoidance. Funded under the Drug Abuse and Addiction Research Programs (CFDA 93.279), the grant to the Medical University of South Carolina will examine cellular mechanisms by which serotonin and glutamate receptors in the rostromedial tegmental nucleus drive aversive conditioning...

Federal Grant Award Summary Praeventix LLC received a $355,190 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded June 1, 2026, with a completion date of May 31, 2027. The award funds in vivo characterization studies of 5-HT7 modulators, specifically the lead compound PRA078, in rat models of opioid use disorder (OUD). The research evaluates how antagonism of the 5-HT7 receptor regulates dopamine pathways...